Ask AI
ProCE Banner Activity

Experts Discuss Key Questions Surrounding Treatment of BRAF V600E–Mutated Metastatic CRC and NSCLC

Clinical Thought

In this commentary, experts discuss questions from HCPs participating in a local live meeting series on the management of BRAF V600E–mutated metastatic colorectal and non-small-cell lung cancers, including best practices in testing and targeted therapy and treating special populations.

Released: June 30, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Pfizer Inc.

Pfizer Inc.

Target Audience

This activity is intended for oncologists, oncology nurses and nurse practitioners, physician assistants, pharmacists, and other healthcare professionals involved in the care and treatment of patients with mCRC and/or mNSCLC in community practices.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply the latest evidence and guideline recommendations for the first-line treatment of patients with BRAF V600E-mutant mCRC and mNSCLC

  • Integrate biomarker testing workflows to improve identification and timely treatment selection for patients with BRAF V600E-mutant mCRC and mNSCLC

  • Implement practical strategies to manage adverse events associated with BRAF-targeted combination therapies through appropriate dose modifications and supportive care

  • Collaborate across multidisciplinary care teams to personalize treatment plans and ensure optimal outcomes for patients with BRAF-mutant mCRC and mNSCLC

Financial Disclosures

Primary Author

Christopher Lieu, MD, FASCO: consultant/advisor/speaker: Pfizer; researcher: Genentech, Janssen.

Gregory J. Riely, MD, PhD: investigator: Amgen; research funding: Lilly; researcher: Pfizer.